Aminoimidazolones and their use as a medicament for treating cognitive impairment. Alzheimer disease, neurodegeneration and dementia.

Details for Australian Patent Application No. 2007259432 (hide)

Owner Astex Therapeutics Ltd AstraZeneca AB

Inventors Rotticci, Didier; Sehgelmeble, Fernando; Holenz, Jorg; Berg, Stefan; Hogdin, Katharina; Kolmodin, Karin; Plobeck, Niklas

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2007259432

PCT Pub. Number WO2007/145570

Priority 60/866,451 20.11.06 US; 60/813,549 14.06.06 US; 60/896,986 26.03.07 US

Filing date 12 June 2007

Wipo publication date 21 December 2007

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

Event Publications

8 January 2009 PCT application entered the National Phase

  PCT publication WO2007/145570 Priority application(s): WO2007/145570

22 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007259433-Aminoimidazolones and their use as a medicament for treating cognitive impairment. alzheimer disease, neurodegeneration and dementia.

2007259425-Benzimidazole derivatives which are to be used as anatgonist for the CB1-receptor